Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3

被引:26
|
作者
Cecilia Rodriguez, Ana [1 ]
Schiffman, Mark [2 ]
Herrero, Rolando [3 ]
Hildesheim, Allan [2 ]
Bratti, Concepcion [1 ]
Sherman, Mark E. [2 ]
Solomon, Diane [4 ]
Guillen, Diego [1 ]
Alfaro, Mario [1 ]
Morales, Jorge [1 ]
Hutchinson, Martha [5 ]
Cheung, Li [6 ]
Wacholder, Sholom [2 ]
Burk, Robert D. [7 ]
机构
[1] INCIENSA Fdn, San Jose, Costa Rica
[2] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Rockville, MD USA
[3] World Hlth Org, Int Agcy Res Canc, Prevent & Implementat Grp, Lyon, France
[4] NCI, Canc Prevent Div, NIH, DHHS, Rockville, MD USA
[5] Womens & Infants Hosp, Providence, RI USA
[6] Informat Management Serv Inc, Silver Spring, MD USA
[7] Albert Einstein Coll Med, Bronx, NY 10467 USA
基金
美国国家卫生研究院;
关键词
HPV infection re-appearance; CIN2+; risk after re-appearance; HPV infection epidemiology; HUMAN-PAPILLOMAVIRUS INFECTION; NATURAL-HISTORY; WOMEN; DURATION; GUANACASTE; INCIDENT; PERSISTENCE; COHORT;
D O I
10.1002/ijc.27418
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carcinogenic human papillomavirus (HPV) infections are very common after sexual debut and nearly all become undetectable (clear) within a few years. Following clearance, the long-term risks of type-specific HPV re-appearance and subsequent risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) are not well defined. In the 7-year, population-based cohort study in Guanacaste, Costa Rica, we studied how often type-specific carcinogenic HPV infections re-appeared after clearance and how often re-appearance led to CIN2+. We considered 1,740 carcinogenic HPV infections detected by MY09/11 PCR among 2,805 women (1891 years old, median 34) who were actively followed at 6- or 12-month intervals. We identified women with one or more type-specific HPV infections that cleared and re-appeared and further defined a subgroup of definite clearance and re-appearance (=2 intervening negative results over a period of =1 year). We determined the absolute risk of CIN2+ among the different groups. p values are two-sided. Only 7.7% (81/1,052) of HPV-infected women had intervening negative results. Very few (3.7%, 39/1,052) had definite clearance and re-appearance, of which 5.1% (2/39) subsequently persisted to a diagnosis of CIN2. There were zero CIN3+ lesions. Extremely few women (2/2,805 of women in our cohort) had a type-specific carcinogenic HPV infection clear, re-appear and lead to CIN2+. If confirmed, this argues against vaccination to avoid re-appearance that leads to precursor lesions and against the need of frequent HPV screening after initial negative results.
引用
收藏
页码:1874 / 1881
页数:8
相关论文
共 50 条
  • [21] HPV 16 Is Related to the Progression of Cervical Intraepithelial Neoplasia Grade 2: A Case Series
    Loffredo D'Ottaviano, Maria Gabriela
    Discacciati, Michelle Garcia
    Andreoli, Maria Antonieta
    Costa, Maria Cecelia
    Termini, Lara
    Rabelo-Santos, Silvia H.
    Villa, Luisa Lina
    Zeferino, Luiz Carlos
    OBSTETRICS AND GYNECOLOGY INTERNATIONAL, 2013, 2013
  • [22] THE HPV E4 IS A CANDIDATE BIOMARKER IN CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2
    Murakami, Isao
    Chiyokura, Ryoko
    Shimada, Sayaki
    Oomura, Ryoko
    Tanaka, Kyoko
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A76 - A77
  • [23] HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia
    Mariska Bierkens
    Saskia M Wilting
    Wessel N van Wieringen
    Mark A van de Wiel
    Bauke Ylstra
    Chris JLM Meijer
    Peter JF Snijders
    Renske DM Steenbergen
    BMC Cancer, 12
  • [24] Erratum: Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England
    R Howell-Jones
    A Bailey
    S Beddows
    A Sargent
    N de Silva
    G Wilson
    J Anton
    T Nichols
    K Soldan
    H Kitchener
    British Journal of Cancer, 2010, 103 : 928 - 928
  • [25] The risk of cervical cancer following active surveillance for cervical intraepithelial neoplasia grade 2
    Lycke, Kathrine Dyhr
    Kahlert, Johnny
    Petersen, Lone Kjeld
    Damgaard, Rikke Kamp
    Cheung, Li C.
    Gravitt, Patti
    Hammer, Anne
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2023, 102 : 83 - 83
  • [26] Genotype, cervical intraepithelial neoplasia, and type-specific cervical intraepithelial neoplasia distributions in hrHPV plus cases referred to colposcopy: A multicenter study of Chinese mainland women
    Chen, Mingyang
    Ye, Zichen
    Wang, Huike
    Cui, Xiaoli
    Seery, Samuel
    Wu, Aiyuan
    Xue, Peng
    Qiao, Youlin
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (03)
  • [27] Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3
    Giannella, Luca
    Rossi, Paolo Giorgi
    Carpini, Giovanni Delli
    Di Giuseppe, Jacopo
    Bogani, Giorgio
    Gardella, Barbara
    Monti, Ermelinda
    Liverani, Carlo Antonio
    Ghelardi, Alessandro
    Insinga, Salvatore
    Raspagliesi, Francesco
    Spinillo, Arsenio
    Vercellini, Paolo
    Roncella, Elena
    Ciavattini, Andrea
    GYNECOLOGIC ONCOLOGY, 2021, 161 (03) : 741 - 747
  • [28] Negative HPV testing among patients with biopsy-proven cervical intraepithelial neoplasia grade 2/3 or cervical cancer
    Gonzalez-Bosquet, Eduardo
    Fernandez, Sergi
    Sabra, Sally
    Lailla, Jose M.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2017, 136 (02) : 229 - 231
  • [29] Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation
    Heymans, Julie
    Benoy, Ina H.
    Poppe, Willy
    Depuydt, Christophe E.
    INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (04) : 903 - 909
  • [30] Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear
    Berkhof, Johannes
    Bulkmans, Nicole W. J.
    Bleeker, Maaike C. G.
    Bulk, Saskia
    Snijders, Peter J. F.
    Voorhorst, Feja J.
    Meijer, Chris J. L. M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (07) : 1268 - 1273